These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 23538857)
1. Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer. Kharbanda A; Rajabi H; Jin C; Raina D; Kufe D Mol Cancer Res; 2013 Jul; 11(7):714-23. PubMed ID: 23538857 [TBL] [Abstract][Full Text] [Related]
2. Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. Jin C; Rajabi H; Pitroda S; Li A; Kharbanda A; Weichselbaum R; Kufe D PLoS One; 2012; 7(7):e39432. PubMed ID: 22792175 [TBL] [Abstract][Full Text] [Related]
3. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457 [TBL] [Abstract][Full Text] [Related]
4. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells. Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366 [TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444 [TBL] [Abstract][Full Text] [Related]
6. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer. Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377 [No Abstract] [Full Text] [Related]
8. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007 [TBL] [Abstract][Full Text] [Related]
9. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772 [TBL] [Abstract][Full Text] [Related]
10. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Wen J; Li R; Lu Y; Shupnik MA Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112 [TBL] [Abstract][Full Text] [Related]
12. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells. Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830 [TBL] [Abstract][Full Text] [Related]
13. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808 [TBL] [Abstract][Full Text] [Related]
14. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms. Long X; Fan M; Bigsby RM; Nephew KP Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020 [TBL] [Abstract][Full Text] [Related]
16. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Alam M; Rajabi H; Ahmad R; Jin C; Kufe D Oncotarget; 2014 May; 5(9):2622-34. PubMed ID: 24770886 [TBL] [Abstract][Full Text] [Related]
17. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis. Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856 [TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302 [TBL] [Abstract][Full Text] [Related]
20. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Jin K; Kong X; Shah T; Penet MF; Wildes F; Sgroi DC; Ma XJ; Huang Y; Kallioniemi A; Landberg G; Bieche I; Wu X; Lobie PE; Davidson NE; Bhujwalla ZM; Zhu T; Sukumar S Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2736-41. PubMed ID: 21690342 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]